SYRE
Spyre Therapeutics Inc.
89.90$
+1.0%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -180.5% | -407.1% | -472.9% | -828.0% | – | – | -286.7% | -3,441.1% | -11,276.5% | -17,766.4% | – | |
| – | 1.5% | 2.9% | 4.8% | 7.5% | – | – | 8.4% | 67.3% | 84.0% | 84.0% | – | |
| – | 12.6% | – | – | – | – | – | 42.9% | 305.3% | 2,897.9% | 5,060.2% | – | |
| – | -21.9% | 31.3% | -3.8% | 185.2% | – | – | 9.8% | -236.3% | -587.6% | -511.7% | – | |
| – | 3.4% | 4.6% | 11.9% | 10.9% | – | – | 3.1% | 1.6% | 0.0% | 0.0% | – | |
| – | -66.0% | -262.7% | -432.8% | -391.7% | – | – | -120.7% | 2,447.7% | – | -39,874.2% | – | |
| – | -33.3% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -2.7% | -17.9% | -1.8% | 0.0% | – | |
| – | 684.9% | 1,066.8% | 234.6% | 1,467.8% | – | – | 7.4% | 1,832.5% | 40,753.6% | 46,377.7% | – | |
| – | 438.4% | 397.0% | -671.1% | 248.0% | – | – | -400.0% | 834.5% | 17,245.9% | -11,263.2% | – | |
| – | -183.9% | -411.7% | -484.8% | -838.9% | – | – | -289.7% | -3,442.8% | -11,276.5% | -17,766.4% | – |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.